Apelin protects against sepsis‑induced cardiomyopathy by inhibiting the TLR4 and NLRP3 signaling pathways

International Journal of Molecular Medicine
Qiancheng LuoMingming Jin

Abstract

The mechanism underlying sepsis‑induced cardiomyopathy (SICM) remains unclear. The aim of the present study was therefore to illuminate the mechanisms and effects of apelin on SICM, using both patient clinical features and a sepsis rat model. A total of 73 adult patients with or without sepsis were analyzed. Male rats were used to generate the sepsis model through cecal ligation and puncture (CLP). The clinical analysis results demonstrated that sepsis induced cardiac dysfunction, including a decrease of left ventricular end‑diastolic dimension, fractional shortening, ejection fraction, left ventricular end‑systolic dimension, and stroke volume, compared with healthy controls. In addition, the results demonstrated that white blood cell count and inflammatory cytokine expression increased in sepsis patients compared with healthy controls. ELISA analyses revealed that apelin was upregulated following sepsis. The animal model study demonstrated that rats treated with apelin had significantly reduced mortality and suppressed sepsis‑induced myocardial damage and inflammatory responses, through suppression of activation of the Toll‑like receptor 4 (TLR4) and NLR family pyrin domain containing 3 (NLRP3) signaling pathways. Taken toget...Continue Reading

References

Feb 20, 2010·Nature Reviews. Immunology·Jurg Tschopp, Kate Schroder
Mar 11, 2010·Protein and Peptide Letters·Jochen HinkelbeinRobert E Feldmann
Jun 7, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Tuanzhu HaChuanfu Li
Apr 16, 2014·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·Mengjing XiaoHaijun Zhang
Nov 14, 2015·Journal of Intensive Care·Ryota Sato, Michitaka Nasu
Mar 25, 2016·Journal of Intensive Care·Yasuyuki KakihanaTomotsugu Yasuda
Apr 26, 2016·Molecular Medicine Reports·Xuemin ZhangFang Wu
May 8, 2016·Journal of the American Society of Nephrology : JASN·Jianmin ChenChristoph Thiemermann
Jun 14, 2016·Mediators of Inflammation·Emanuela TurillazziConsolato Sergi
Jun 28, 2016·European Journal of Pharmacology·Qin ZhouDongsheng Xiong
Oct 27, 2016·BMB Reports·Min-Ji KimJi-Hwan Ryu
Aug 21, 2016·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Miriam KalbitzPeter A Ward
Dec 30, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Liliang JinSamithamby Jeyaseelan
Jan 26, 2017·Cytokine·Panagiotis PapadopoulosSotirios Tsiodras
Feb 17, 2017·Biochemical and Biophysical Research Communications·Rujun LiZhengang Zhang
Mar 1, 2017·American Journal of Respiratory and Critical Care Medicine·Seonmin LeeAugustine M K Choi
May 21, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Xu ZhangJunguo Duan
Jun 9, 2017·International Immunopharmacology·Qian-Hang ShaoNai-Hong Chen
Jul 20, 2017·Nature Immunology·Inna S AfoninaRudi Beyaert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.